Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Julie J. Miller; L. Nicolas Gonzalez Castro; Samuel McBrayer; Michael Weller; Timothy Cloughesy; Jana Portnow; Ovidiu Andronesi; Jill S. Barnholtz-Sloan; Brigitta G. Baumert; Mitchell S. Berger; Wenya Linda Bi; Ranjit Bindra; Daniel P. Cahill; Susan M. Chang; Joseph F. Costello; Craig Horbinski; Raymond Y. Huang; Robert B. Jenkins; Keith L. Ligon; Ingo K. Mellinghoff; L. Burt Nabors; Michael Platten; David A. Reardon; Diana D. Shi; David Schiff; Wolfgang Wick; Hai Yan; Andreas von Deimling; Martin van den Bent; William G. Kaelin; Patrick Y. Wen

doi:10.1093/neuonc/noac207

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Jana Portnow, Ovidiu Andronesi, Jill S. Barnholtz-Sloan, Brigitta G. Baumert, Mitchell S. Berger, Wenya Linda Bi, Ranjit Bindra, Daniel P. Cahill, Susan M. Chang, Joseph F. Costello, Craig Horbinski, Raymond Y. Huang, Robert B. Jenkins, Keith L. Ligon, Ingo K. MellinghoffL. Burt Nabors, Michael Platten, David A. Reardon, Diana D. Shi, David Schiff, Wolfgang Wick, Hai Yan, Andreas von Deimling, Martin van den Bent, William G. Kaelin, Patrick Y. Wen

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

Abstract

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.

Original language	English (US)
Pages (from-to)	4-25
Number of pages	22
Journal	Neuro-oncology
Volume	25
Issue number	1
DOIs	https://doi.org/10.1093/neuonc/noac207
State	Published - Jan 5 2023

Keywords

D-2HG
Isocitrate dehydrogenase (IDH)
glioma

ASJC Scopus subject areas

Oncology
Clinical Neurology
Cancer Research

Access to Document

10.1093/neuonc/noac207

Cite this

Miller, J. J., Gonzalez Castro, L. N., McBrayer, S., Weller, M., Cloughesy, T., Portnow, J., Andronesi, O., Barnholtz-Sloan, J. S., Baumert, B. G., Berger, M. S., Bi, W. L., Bindra, R., Cahill, D. P., Chang, S. M., Costello, J. F., Horbinski, C., Huang, R. Y., Jenkins, R. B., Ligon, K. L., ... Wen, P. Y. (2023). Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-oncology, 25(1), 4-25. https://doi.org/10.1093/neuonc/noac207

Miller, JJ, Gonzalez Castro, LN, McBrayer, S, Weller, M, Cloughesy, T, Portnow, J, Andronesi, O, Barnholtz-Sloan, JS, Baumert, BG, Berger, MS, Bi, WL, Bindra, R, Cahill, DP, Chang, SM, Costello, JF, Horbinski, C, Huang, RY, Jenkins, RB, Ligon, KL, Mellinghoff, IK, Nabors, LB, Platten, M, Reardon, DA, Shi, DD, Schiff, D, Wick, W, Yan, H, von Deimling, A, van den Bent, M, Kaelin, WG & Wen, PY 2023, 'Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions', Neuro-oncology, vol. 25, no. 1, pp. 4-25. https://doi.org/10.1093/neuonc/noac207

@article{7796cd2ed7fe4d558a9dd7447f37ced1,

title = "Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions",

abstract = "Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.",

keywords = "D-2HG, Isocitrate dehydrogenase (IDH), glioma",

author = "Miller, {Julie J.} and {Gonzalez Castro}, {L. Nicolas} and Samuel McBrayer and Michael Weller and Timothy Cloughesy and Jana Portnow and Ovidiu Andronesi and Barnholtz-Sloan, {Jill S.} and Baumert, {Brigitta G.} and Berger, {Mitchell S.} and Bi, {Wenya Linda} and Ranjit Bindra and Cahill, {Daniel P.} and Chang, {Susan M.} and Costello, {Joseph F.} and Craig Horbinski and Huang, {Raymond Y.} and Jenkins, {Robert B.} and Ligon, {Keith L.} and Mellinghoff, {Ingo K.} and Nabors, {L. Burt} and Michael Platten and Reardon, {David A.} and Shi, {Diana D.} and David Schiff and Wolfgang Wick and Hai Yan and {von Deimling}, Andreas and {van den Bent}, Martin and Kaelin, {William G.} and Wen, {Patrick Y.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",

year = "2023",

month = jan,

day = "5",

doi = "10.1093/neuonc/noac207",

language = "English (US)",

volume = "25",

pages = "4--25",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Isocitrate dehydrogenase (IDH) mutant gliomas

T2 - A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

AU - Miller, Julie J.

AU - Gonzalez Castro, L. Nicolas

AU - McBrayer, Samuel

AU - Weller, Michael

AU - Cloughesy, Timothy

AU - Portnow, Jana

AU - Andronesi, Ovidiu

AU - Barnholtz-Sloan, Jill S.

AU - Baumert, Brigitta G.

AU - Berger, Mitchell S.

AU - Bi, Wenya Linda

AU - Bindra, Ranjit

AU - Cahill, Daniel P.

AU - Chang, Susan M.

AU - Costello, Joseph F.

AU - Horbinski, Craig

AU - Huang, Raymond Y.

AU - Jenkins, Robert B.

AU - Ligon, Keith L.

AU - Mellinghoff, Ingo K.

AU - Nabors, L. Burt

AU - Platten, Michael

AU - Reardon, David A.

AU - Shi, Diana D.

AU - Schiff, David

AU - Wick, Wolfgang

AU - Yan, Hai

AU - von Deimling, Andreas

AU - van den Bent, Martin

AU - Kaelin, William G.

AU - Wen, Patrick Y.

N1 - Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2023/1/5

Y1 - 2023/1/5

N2 - Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.

AB - Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.

KW - D-2HG

KW - Isocitrate dehydrogenase (IDH)

KW - glioma

UR - http://www.scopus.com/inward/record.url?scp=85145955252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145955252&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noac207

DO - 10.1093/neuonc/noac207

M3 - Article

C2 - 36239925

AN - SCOPUS:85145955252

SN - 1522-8517

VL - 25

SP - 4

EP - 25

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 1

ER -

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this